Log in to save to my catalogue

Estimation of the effect of atezolizumab plus bevacizumab on pulmonary arterial hypertension using c...

Estimation of the effect of atezolizumab plus bevacizumab on pulmonary arterial hypertension using c...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_de4d5e3fc7164a0cb2c301cc50e1d96f

Estimation of the effect of atezolizumab plus bevacizumab on pulmonary arterial hypertension using computed tomography in HCC patients

About this item

Full title

Estimation of the effect of atezolizumab plus bevacizumab on pulmonary arterial hypertension using computed tomography in HCC patients

Publisher

London: Nature Publishing Group UK

Journal title

Scientific reports, 2023-07, Vol.13 (1), p.11524-11524, Article 11524

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

The effect of the combination of atezolizumab and bevacizumab (Atez/Bev) for hepatocellular carcinoma (HCC) on pulmonary arterial hypertension (PAH) is unknown. Estimation of PAH by using computed tomography (CT) has recently been proposed. Thus, we aimed to estimate the effect of Atez/Bev on PAH using CT. Altogether, 113 patients who received Atez...

Alternative Titles

Full title

Estimation of the effect of atezolizumab plus bevacizumab on pulmonary arterial hypertension using computed tomography in HCC patients

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_de4d5e3fc7164a0cb2c301cc50e1d96f

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_de4d5e3fc7164a0cb2c301cc50e1d96f

Other Identifiers

ISSN

2045-2322

E-ISSN

2045-2322

DOI

10.1038/s41598-023-38377-2

How to access this item